Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

ully completed two Phase 3 trials of Pruvel™ a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the ability of fidaxomicin to treat CDI and address current treatment limitations and the potential for fidaxomicin to be a treatment of choice for CDI. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs, the development of alternative treatments for or means of preventing CDI, whether regulatory authorities will review or approve Optimer's applications for marketing approval, the timing of any marketing approvals, Optimer's ability to complete its NDA submission in a timely manner, Optimer's ability to commercialize any products for which it receives marketing approval, whether healthcare professionals will prescribe fidaxomicin, if approved, whether fidaxomicin will receive reimbursement coverage from healthcare payors and government agencies and other risks detailed in Optimer's filings with the Securities and Exchange Commission. ContactsOptimer Ph
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 E-QURE Corp. (OTCQB: EQUR), ... Bio-electrical Signal Therapy device ("BST Device"), a new and ... heal chronic wounds, today announced that the Company has ... distributor specializing in medical devices, for the marketing and ... a 70 years old, sales, marketing and distribution company ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 ... "Global Market Study on 3D Cell Culture: ... published by Persistence Market Research, the global 3D cell culture ... is expected to expand at a CAGR of 29.1% ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:8/3/2015)... ... 2015 , ... Sterlitech Corporation introduces the compact, quiet, and ... laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free design, ... solution for a broad range of vacuum filtration applications. , Featuring a 1/7 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4Sterlitech Launches New Line of Vacuum Pumps 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4
... Area Economic Development Corporation 's annual business-plan contest is starting ... the best business ideas from Eau Claire County. , ,For ... on March 29. Then entrants in the Creating Your ... prepare their applications. , ,Businesses judged to have the best ...
... Metavante Corporation has completed its acquisition of ... says it is expanding its Healthcare Payments Solutions ... Reynolds, who previously served as senior vice president ... Wells Fargo Institutional Trust Service, will become president ...
... , a local software and consulting firm, has teamed ... a new geographic information systems application, the companies said ... to create and distribute land records data through a ... challenges faced by organizations trying to maintain and distribute ...
Cached Biology Technology:
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 /PRNewswire/ ... and services for gene function analysis and biomarker ... Guide RNA (sgRNA) Knockout Library targeting all human ... specifically and permanently "knock out" a gene,s function. ... provides a high throughput screening tool so that ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... a climate as prone to extremes as Canada,s, buildings ... innovative solutions are being explored through the NSERC Smart ... initiative headquartered at Concordia, which has just received $1 ... "Through the ecoENERGY Innovation Initiative, our Government ...
... MNMay 2, 2013UnitedHealth Group and the Minneapolis Heart Institute ... of New Ulm, Minn., recently announced two grants from ... will fund weight management and nutrition initiatives for Hearts ... a research and demonstration project with a goal of ...
... to announce the launch of Environmental Science & ... accelerate the pace of research across the environmental field ... leading publishing outlet to highlight urgent critical findings in ... release its first issue January 2014 and open for ...
Cached Biology News:$1 million for smart energy solutions 2UnitedHealth Group grants more than $1 million for the heart of New Ulm project 2New ACS journal Environmental Science and Technology Letters to rapidly publish urgent research 2New ACS journal Environmental Science and Technology Letters to rapidly publish urgent research 3
... ULS cDNA Synthesis and Labeling Kit generates ... experiments. First unmodified cDNA is made via ... using an Oligo(dT) primer. Unlike other methods, ... in the reverse transcription reaction. This unmodified ...
... enables fully automated hybridization of microarrays on ... been designed to offer researchers improved reproducibility, ... perform a wide range of applications. ... 485C; denaturations of up to 99C. The ...
... The user-friendly Eppendorf Thermomixer R offers ... that require shaking, heating, and cooling. ... expanded its application and temperature control ... each accommodate 24 micro test tubes, ...
... a high quality microarray scanner based on patented ... and spatial resolution. The DNAscope LM is ... microarray scanner that is upgradeable to a total ... Includes control module (computer), monitor, ...
Biology Products: